Hamid Feroze, MD
Cardiovascular Disease · Roswell, NMNPI 1568425395
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,190 of the $4,291 with a category attached, or 74.4%. 22 manufacturers reported payments, led by Medtronic at 38.2% of the total. Reporting peaked in 2023 at $2,063 and has fallen 86.2% since, to $285 in 2025.
Across 156 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Pfizer$436
- Boehringer Ingelheim$390
- Novartis$344
- Boston Scientific$230
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$224
- plus $1K from 16 others
What the payments were for
- Travel & lodging$1,09526%
- Food & beverage$3,19074%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $1,641 |
| Pfizer | 26 | $436 |
| Boehringer Ingelheim | 20 | $390 |
| Novartis | 20 | $344 |
| Boston Scientific | 12 | $230 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $224 |
| Abbott | 5 | $199 |
| Johnson & Johnson | 12 | $183 |
| E.r. Squibb & Sons, L.L.C. | 7 | $132 |
| Merck | 5 | $89 |
| AstraZeneca | 5 | $73 |
| Surmodics, Inc. | 1 | $67 |
| Amgen | 4 | $62 |
| Bayer | 2 | $42 |
| Olympus America Inc. | 1 | $40 |
| Axonics, Inc. | 1 | $28 |
| Abiomed | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 2 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Shockwave Medical, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,291 in reported general payments places this provider in the 75th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 758 | $699,938 |
| XareltoRivaroxaban | 129 | $117,010 |
| EntrestoSacubitril/Valsartan | 76 | $62,625 |
| FarxigaDapagliflozin Propanediol | 78 | $52,870 |
| JardianceEmpagliflozin | 40 | $43,818 |
| Repatha SureclickEvolocumab | 44 | $29,633 |
| BrilintaTicagrelor | 24 | $15,676 |
| Metoprolol Succinate | 784 | $11,128 |
| Atorvastatin Calcium | 825 | $9,426 |
| Potassium Chloride | 707 | $7,444 |
| Nifedipine ErNifedipine | 273 | $6,344 |
| Losartan Potassium | 505 | $5,532 |
| Amiodarone Hcl | 279 | $4,735 |
| Ezetimibe | 297 | $4,502 |
| ClopidogrelClopidogrel Bisulfate | 331 | $3,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $436 | $699,938758 claims |
| Johnson & JohnsonXarelto | $183 | $117,010129 claims |
| AstraZenecaFarxiga, Brilinta | $73 | $68,545102 claims |
| NovartisEntresto | $344 | $62,62576 claims |
| Boehringer IngelheimJardiance | $390 | $43,81840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 cardiovascular disease providers in New Mexico.
Other cardiovascular disease in Roswell
- Fundador AdajarRoswell$8K
- Eric CohenRoswell$2K
- Abinash AchrekarAlbuquerque$88K
- Suresh NeelagaruChama$46K
- Adam BanksAlbuquerque$38K
- Jose Rodriguez ArciniegaLas Cruces$24K
- Stacey CleggAlbuquerque$21K
- Leonardo MaciasAlbuquerque$15K
- William RobinsonFarmington$14K
- Muhammad AnwarLas Cruces$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.